title: Myxoma and vaccinia viruses bind differentially to human leukocytes.
abstract: Myxoma virus (MYXV) and vaccinia virus (VACV), two distinct members of the family Poxviridae, are both currently being developed as oncolytic virotherapeutic agents. Recent studies have demonstrated that ex vivo treatment with MYXV can selectively recognize and kill contaminating cancerous cells from autologous bone marrow transplants without perturbing the engraftment of normal CD34(+) hematopoietic stem and progenitor cells. However, the mechanism(s) by which MYXV specifically recognizes and eliminates the cancer cells in the autografts is not understood. While little is known about the cellular attachment factor(s) exploited by MYXV for entry into any target cells, VACV has been shown to utilize cell surface glycosaminoglycans such as heparan sulfate (HS), the extracellular matrix protein laminin, and/or integrin β1. We have constructed MYXV and VACV virions tagged with the Venus fluorescent protein and compared their characteristics of binding to various human cancer cell lines as well as to primary human leukocytes. We report that the binding of MYXV or VACV to some adherent cell lines could be partially inhibited by heparin, but laminin blocked only VACV binding. In contrast to cultured fibroblasts, the binding of MYXV and VACV to a wide spectrum of primary human leukocytes could not be competed by either HS or laminin. Additionally, MYXV and VACV exhibited very different binding characteristics against certain select human leukocytes, suggesting that the two poxviruses utilize different cell surface determinants for the attachment to these cells. These results indicate that VACV and MYXV can exhibit very different oncolytic tropisms against some cancerous human leukocytes.
authors: Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, Florida, USA.
authors: Winnie M
authors: WM
authors: Chan
authors: Eric C
authors: EC
authors: Bartee
authors: Jan S
authors: JS
authors: Moreb
authors: Ken
authors: K
authors: Dower
authors: John H
authors: JH
authors: Connor
authors: Grant
authors: G
authors: McFadden
mesh_terms: D045744:Cell Line, Tumor; D006801:Humans; D007962:Leukocytes / Q000821:virology*; D009233:Myxoma virus / Q000502:physiology*; D014616:Vaccinia virus / Q000502:physiology*; D053585:Virus Attachment
references: J Virol. 1996 Oct;70(10):6909-21
references: 8794334
references: Microbes Infect. 2010 Dec;12(14-15):1144-52
references: 20832500
references: Blood. 2012 Mar 29;119(13):3128-31
references: 22310910
references: Viral Immunol. 2002;15(2):229-46
references: 12081009
references: Br Med Bull. 1959 Sep;15:240-5
references: 13822176
references: Virol J. 2004 Nov 22;1:10
references: 15555076
references: J Virol. 1998 Oct;72(10):8374-9
references: 9733888
references: J Virol Methods. 2004 Dec 1;122(1):63-72
references: 15488622
references: J Virol. 2009 Jan;83(2):498-511
references: 18971273
references: J Virol. 1998 Feb;72(2):1577-85
references: 9445060
references: Virology. 2012 Nov 25;433(2):506-12
references: 22999097
references: J Virol. 2000 Apr;74(7):3353-65
references: 10708453
references: Virology. 2010 Jun 5;401(2):266-79
references: 20334889
references: Mol Ther. 2012 Apr;20(4):749-58
references: 22186794
references: Curr Protoc Microbiol. 2010 May;Chapter 14:Unit 14A.1
references: 20440681
references: Antiviral Res. 2012 Mar;93(3):387-415
references: 22333483
references: Virology. 2009 Jun 20;389(1-2):132-40
references: 19428041
references: Expert Opin Biol Ther. 2007 Sep;7(9):1415-25
references: 17727330
references: Expert Rev Vaccines. 2010 Dec;9(12):1353-6
references: 21105770
references: J Biol Chem. 1995 Feb 17;270(7):3031-8
references: 7852384
references: Mol Gen Mikrobiol Virusol. 2012;(1):8-15
references: 22702138
references: EMBO J. 1996 May 15;15(10):2343-55
references: 8665841
references: Methods Mol Biol. 2012;797:205-15
references: 21948478
references: J Virol. 2005 Apr;79(8):4755-63
references: 15795261
references: J Virol. 2003 May;77(10):5877-88
references: 12719581
references: Biol Blood Marrow Transplant. 2012 Oct;18(10):1540-51
references: 22516053
references: Nat Rev Microbiol. 2005 Mar;3(3):201-13
references: 15738948
references: J Virol. 2012 Jun;86(12):6677-87
references: 22496232
references: Virology. 2009 Mar 15;385(2):368-82
references: 19162289
references: Cancer Res. 2010 Jan 15;70(2):598-608
references: 20068158
references: Viruses. 2012 May;4(5):688-707
references: 22754644
references: Virus Res. 2002 Sep;88(1-2):17-33
references: 12297325
references: J Virol. 2005 Aug;79(16):10397-407
references: 16051832
references: Nat Rev Cancer. 2009 Jan;9(1):64-71
references: 19104515
references: Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4640-5
references: 16537421
references: J Virol. 1999 Oct;73(10):8750-61
references: 10482629
references: Curr Opin Virol. 2012 Feb;2(1):20-7
references: 22440962
references: Cytokine. 2009 Sep;47(3):199-205
references: 19640730
references: Virology. 1999 Nov 25;264(2):298-318
references: 10562494
references: Leukemia. 2009 Dec;23(12):2313-7
references: 19865109
references: Semin Immunol. 2001 Feb;13(1):73-84
references: 11289802
references: Expert Opin Biol Ther. 2011 May;11(5):595-608
references: 21338330
references: J Virol. 2010 Apr;84(7):3287-302
references: 20106927
references: J Virol. 2007 Mar;81(5):2149-57
references: 17166913